| Penwest Pharmaceuticals Co. Q1 2010 Earnings Call Transcript Penwest Pharmaceuticals Co. (PPCO)Q1 2010 Earnings Call TranscriptMay 3, 2010 10:00 am ETComplete Story » seekingalpha.com |
When Older Drivers Excel Though younger drivers are widely believed to have quicker reaction times, drivers with more experience behind the wheel are more aware of potential hazards of the road. online.wsj.com |
NIH to Fight Against Rare Diseases A government program focusing on rare diseases has launched five pilot projects that are taking the National Institutes of Health in a new direction: developing drugs. online.wsj.com |
Three Biotech Stocks With Pending News Developments, Catalysts M.E. Garza submits: As always, we are chasing several stories and hearing whispers that may be of interest to readers. The first of these involves Access Pharmaceuticals, Inc. (ACCP.OB). The word on the street is that the company is getting ready to announce its first commercial order for MuGard. The order should bring the company close to $1 million in revenue and could come as part of that exclusive specialty distribution deal that Access signed with BioScrip (BIOS) in July. Access has been given comprehensive access to BioScrip's nationwide distribution platform, which includes extensive physician relationships, over 100 specialty pharmacies, a mail distribution network and more. If the rumor is true, this will be a significant step for Access, because it will mark a new phase for the company.Patients who have been waiting for this FDA-approved oral wound rinse will be the real winners, of course. MuGuard has been used by many very effectively for the management of oral mucositis, a painful inflammation and ulceration of the mucous membranes which is a debilitating side effect of radiation treatment and chemotherapy. Zacks Investment Research recently issued an update summarizing some of the recent positive developments at Access and they reiterated an 'Outperform' rating with a six-twelve month price target of $8.00. The stock closed Monday's session at $1.95 +0.02 (1.04%) and charts show a 52-week high of $3.70.Complete Story » seekingalpha.com |
Study Backs Simpler CPR Technique People who suffered cardiac arrest and received chest compressions from bystanders had higher survival rates than those given standard resuscitation that included mouth-to-mouth breathing, a new study found. online.wsj.com |